Teva Pharmaceutical (TEVA) said Tuesday it has received the US Food and Drug Administration's acceptance and the European Medicines Agency's validation for its applications of TVB-009P, a biosimilar candidate to Prolia to treat osteoporosis in postmenopausal women.
The company anticipates the FDA's expected decision and EMA's expected opinion in H2 next year, Teva added.
TVB-009P is the first of the firm's internally developed biosimilars to be submitted in the US, the company said.
Price: 17.37, Change: +0.09, Percent Change: +0.52
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments